OnKure Therapeutics
OKUR
51 hedge funds and large institutions have $114M invested in OnKure Therapeutics in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 9 closing their positions.
256% more capital invested
Capital invested by funds: $32M → $114M (+$82M)
128.02% more ownership
Funds ownership: 85.96% → 213.98% (+128%)
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
16% more funds holding
Funds holding: 44 → 51 (+7)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.3M |
| 2 |
SG
StepStone Group
La Jolla,
California
|
+$6.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$6.11M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.95M |
| 5 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
+$4.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
-$2M |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$1.57M |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$1.07M |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$885K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$573K |
OKUR Hedge Fund Activity: Q1 2026 in Review
51 of the 8,198 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q1 2026, worth a combined $114M — up 256% from $32M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new OKUR positions and 9 closed out — a net gain of 9 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $12.3M. The largest seller was Shay Capital, cutting an estimated $2M.
- 51 institutional investors held OnKure Therapeutics (OKUR) as of Q1 2026, up from 44 in Q4 2025.
- Funds reported $114M of OnKure Therapeutics stock for Q1 2026, up 256% quarter-over-quarter.
- 18 funds opened new OnKure Therapeutics positions in Q1 2026 and 9 closed out, a net change of +9 holders.
- The largest OnKure Therapeutics buyer in Q1 2026 was RA Capital Management, an estimated $12.3M added.
- The largest OnKure Therapeutics seller in Q1 2026 was Shay Capital, an estimated $2M sold.
Based on aggregated 13F filings for Q1 2026.